Table 2.
Baseline characteristics of the total study population after propensity score matching (1:1)
| NHRs with currenta use of therapeutic dose anticoagulant (P1, after 1:1 propensity score matching) (n = 723) | NHRs with no current use of therapeutic dose anticoagulant (P2, after 1:1 propensity score matching) (n = 723) | P-value | SMD | |
|---|---|---|---|---|
| Demographical data | ||||
| Age (mean in years), med (IQR) | 85.7 (7.4) | 85.4 (8.08) | 0.394 | 0.045 |
| Sex, n (%) Male Female |
293 (40.5) 430 (59.5) |
275 (38.0) 448 (62.0) |
0.360 | 0.051 |
| Clinical data Co-morbidities (n, %) |
||||
| Congestive heart failure | 12 (1.7) | 1 (0.1) | 0.005 | 0.162 |
| Hypertension | 0 (0) | 0 (0) | NA | <0.001 |
| Obesity | 26 (3.6) | 21 (2.9) | 0.553 | 0.039 |
| Dementia | 416 (57.5) | 426 (58.9) | 0.631 | 0.028 |
| Cardiovascular disease | 645 (89.2) | 645 (89.2) | 1.000 | <0.001 |
| Cerebrovascular disease | 400 (55.3) | 407 (56.3) | 0.751 | 0.019 |
| Diabetes mellitus | 205 (28.4) | 214 (29.6) | 0.643 | 0.027 |
| Pulmonary disease | 171 (23.7) | 161 (22.3) | 0.574 | 0.033 |
| Renal insufficiency | 180 (24.9) | 163 (22.5) | 0.323 | 0.055 |
| Parkinson’s disease | 44 (6.1) | 51 (7.1) | 0.524 | 0.039 |
| Type of ward (n, %) | 0.038 | 0.168 | ||
| Psychogeriatrics | 286 (39.6) | 324 (44.8) | ||
| Somatics | 204 (28.2) | 153 (21.2) | ||
| Short-term stayb | 120 (16.6) | 123 (17.0) | ||
| Other ward, not specified | 7 (1.0) | 7 (1.0) | ||
| Time in pandemic (mean) | 42.6 (12.4) | 42.6 (11.89) | 0.918 | 0.005 |
| Days to event (mean, SD) | 27.19 (15.55) | 25.05 (15.88) | 0.010 | 0.137 |
| Outcome (n, %) | ||||
| All- cause mortalityc | 175 (24.2) | 220 (30.4) | 0.009 | 0.140 |
NHRs, nursing home residents.
aCurrent use was defined as the use in the last 30 days before start of COVID-19.
bPrimary care and geriatric rehabilitation.
cMortality within 30 days after diagnose COVID-19.